Skip to main content
Faes Farma S.A. logo

Faes Farma S.A. — Investor Relations & Filings

Ticker · FAE ISIN · ES0134950F36 LEI · 959800FXZQY7U3P1G969 MC Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2024-07-30 Interim / Quarterly Rep…
Country ES Spain
Listing MC FAE

About Faes Farma S.A.

https://faesfarma.com/en/

Faes Farma S.A. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products, healthcare solutions, and animal nutrition products. The company's pharmaceutical division develops treatments for conditions in therapeutic areas including allergy, gastroenterology, and immunology, with key proprietary molecules such as Bilastine, a leading antihistamine, and Calcifediol for Vitamin D deficiency. The animal nutrition business provides nutritional solutions and supplements for sustainable animal production. A core focus of the company is its investment in R&D to develop novel molecules and health solutions for its global markets.

Recent filings

Filing Released Lang Actions
Informe de negocio del primer semestre de 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Informe S1 2024' (First Semester 2024 Report) and contains detailed financial statements, including income statements, cash flow analysis, and business segment performance for the first half of the year. It provides substantive financial data and management analysis rather than just an announcement or a summary. Therefore, it is classified as an Interim/Quarterly Report. H1 2024
2024-07-30 Spanish
Pago dividendo complementario
Notice of Dividend Amount Classification · 99% confidence The document is a short announcement addressed to the 'COMISION NACIONAL DEL MERCADO DE VALORES' (National Securities Market Commission), classifying it as 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). The core content explicitly states the approval and details for the payment of a complementary cash dividend ('dividendo en efectivo complementario') for 2023 results, including the amount per share (0.116 euros) and key dates (Last Trading Date, ExDate, Record Date, Payment Date). This directly corresponds to the definition of 'Notice of Dividend Amount' (DIV). The document length is very short (1055 chars), confirming it is an announcement rather than a full report.
2024-06-25 Spanish
Convocatoria de la Junta General de Accionistas de 2024
AGM Information Classification · 99% confidence The document is an official communication from FAES FARMA, S.A. to the CNMV (Comisión Nacional del Mercado de Valores) announcing the convocation of the General Shareholders' Meeting ('Junta General de Accionistas'). It details the date, location, and the full 'ORDEN DEL DIA' (Agenda), which includes items like the approval of 2023 annual accounts, appointment of a director, approval of the Remuneration Policy, and authorization for a capital increase. This document serves to formally notify shareholders of the meeting and the matters to be voted upon, which aligns perfectly with the purpose of a Proxy Solicitation & Information Statement (PSI), as it provides the necessary information for shareholders to exercise their rights (voting, information requests, representation). While it relates to the AGM, the specific content is the formal notice and agenda/information package for the meeting, making 'PSI' the most precise fit over 'AGM-R' (which is usually the presentation materials *from* the meeting).
2024-05-08 Spanish
Propuesta de nombramiento de consejero ejecutivo
Board/Management Information Classification · 100% confidence The document is a communication from FAES FARMA, S.A. to the 'COMISIÓN NACIONAL DEL MERCADO DE VALORES' (a regulatory body) under the heading 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). The content explicitly details the Board of Directors' decision to propose the appointment of a new executive director (Don Eduardo Recoder de la Cuadra) and the resulting change in the current executive chairman's role to non-executive chairman. This action directly concerns changes in the company's senior management and board structure. This aligns perfectly with the definition for Board/Management Information (MANG). The document length is short (1162 chars), but it contains the substantive announcement itself, not just a notice that an announcement was made.
2024-05-02 Spanish
Informe de negocio del primer trimestre de 2024
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report titled 'Informe Q1 2024'. It contains detailed financial statements, including income statements, revenue breakdowns by business segment and geography, and management commentary on business performance and future guidance. It is not a mere announcement or certification, but the substantive financial report for the first quarter of 2024. Q1 2024
2024-04-26 Spanish
Presentación anual del negocio y perspectivas
Investor Presentation Classification · 99% confidence The document is titled 'Capital Markets Day Faes Farma' and contains detailed slides covering R&D pipeline, commercial strategy, product portfolios (Bilastina, Calcifediol, Mesalazina), and ESG governance. This structure—a comprehensive presentation detailing strategy, pipeline, and recent performance metrics for investors—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, an Earnings Release (ER) which is usually a short press release, or a Call Transcript (CT). The content is designed for strategic communication with the investment community.
2024-03-21 Spanish

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.